Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
Conditions
Brief summary
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1 and survivin.
Interventions
DRUGCWP232291
IV Infusion
Sponsors
JW Pharmaceutical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Able to understand and willing to sign an informed consent form (ICF) prior to initiation of any study-specific procedure and treatment * 18 years of age * 3\. A pathologically confirmed diagnosis of AML or CMML-2 by World Health Organization (WHO) classification that is relapsed or refractory or for which no current therapies are anticipated to result in a durable remission, or MDS by WHO classification are RAEB-1 or RAEB-2 and that have failed at least three cycles of hypomethylating therapy, or primary (PMF), post-polycythemia vera (PPMF) or post-essential thrombocythemia (PTMF) MF by WHO classification, are high-risk category by the Dynamic International Prognostic Scoring System (DIPSS Plus), have ≥1% circulating blasts, and have failed treatment with ruxolitinib * Eastern Cooperative Oncology Group (ECOG) performance score 0-2 * In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. If a patient is on hydroxyurea to control peripheral blood leukemic cell counts, the patient must have discontinued hydroxyurea for at least 24 hours before initiation of treatment with study drug. Persistent clinically significant toxicities from prior chemotherapy must not be greater than grade 1 * Adequate renal function: * Serum creatinine =/\< 2.0mg/dL * Adequate hepatic function: * Total bilirubin \<1.5 x upper limit of normal (ULN), unless considered due to Gilbert's syndrome * Alkaline phosphatase (AP) =/\< 2.5 x ULN * Aspartate transaminase (AST) or alanine transaminase (ALT) ≤3 x ULN, unless considered due to organ leukemic involvement * Women of child-bearing potential (i.e., women who are pre menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive, or double barrier device), and must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study * Able to adhere to the study visit schedule and other protocol requirements
Exclusion criteria
* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure (CHF), cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements * Active heart disease including myocardial infarction (MI) within previous 3 months, symptomatic coronary artery disease (CAD), arrhythmias not controlled by medication, or uncontrolled CHF * Active central nervous system (CNS) disease * Therapy with any other standard or investigational treatment for hematologic malignancy (except hydroxyurea, as mentioned in the inclusion criteria) * Therapy with anticoagulant or antithrombotic agents (including aspirin) within 7 days prior to study drug administration * History of gastrointestinal (GI) hemorrhage * Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C * Pregnant or nursing women. Pregnant and nursing patients are excluded because the effects of CWP232291 on a fetus or nursing child are unknown. * Patients eligible for bone marrow transplant, regardless of age * Patients with FLT3 ITD positive AML or AML patients with other cytogenetic abnormalities who are eligible for trials of other targeted investigational agents from which the investigator feels there is greater benefit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose | Up to 3 weeks after start of injection | If myelosuppression is DLT (Dose-Limiting Toxicity), it will be monitored up to 42 days after start of injection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax as a pharmacokinetic parameter of 'CWP232291' | 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, 24 hours post-dose | Peak Plasma Concentration (Cmax) of 'CWP232291' |
| AUC as a pharmacokinetic parameter of 'CWP232291' | 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, 24 hours post-dose | Area under the plasma concentration versus time curve (AUC) of 'CWP232291' |
| Cmax as a pharmacokinetic parameter of metabolites of 'CWP232291' | 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, 24 hours post-dose | Peak Plasma Concentration (Cmax) of metabolites of 'CWP232291' |
| AUC as a pharmacokinetic parameter of metabolites of 'CWP232291' | 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, 24 hours post-dose | Area under the plasma concentration versus time curve (AUC) of metabolites of 'CWP232291' |
Countries
South Korea, United States
Outcome results
None listed